Trade MiMedx Group Inc - MDXG CFD

MiMedx Company profile

About MiMedx Group Inc

MiMedx Group, Inc. is utilizing amniotic tissue as a platform for regenerative medicine, developing and distributing placental tissue allografts for multiple sectors of healthcare. The Company is focused on addressing the needs of patients with acute and chronic non-healing wounds, and a late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. The Company’s platform technologies include AmnioFix, EpiFix, EpiCord, AmnioCord and AmnioFill. Its AmnioFix and EpiFix are its tissue allografts derived from the amnion and chorion layers of the human placental membrane. The EpiCord and AmnioCord are tissue allografts derived from umbilical cord tissue. Its AmnioFill is a particulate product comprised of placental connective tissue matrix, derived from the placental disc and placental membranes.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, MiMedx Group Inc revenues increased 4% to $258.6M. Net loss applicable to common stockholders decreased 80% to $16.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Investigation, restatement and related decrease of 94% to $3.8M (expense), Loss on extinguishment of debt decrease from $8.2M (expense) to

Equity composition

Common Stock $.001 Par, 03/11, 100M auth., 64,331,910 issd., less 50,000 shs. in Treas. @ $25K. Insiders own approx. 18.35%.